Jose Luis Eduardo Doval Caballero

Dr. Jose Luis Eduardo Doval Caballero

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
Jose Luis Eduardo Doval CaballeroJose Luis Eduardo Doval Caballero
Jose Luis Eduardo Doval Caballero
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
GEGenesis Dinora Eugenio-Ponce
Genesis Dinora Eugenio-Ponce
MGManuel Ramon García-Sáenz
Manuel Ramon García-Sáenz
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
CMCésar Alejandro Méndez-Hernández
César Alejandro Méndez-Hernández
The perception of taste is a complex physiological process that extends far beyond the simple detection of flavor molecules, serving as a critical interface between nutrient sensing, metabolic regulation, and feeding behavior. Emerging evidence reveals that this process is profoundly modulated by endocrine and neuromodulatory systems, creating a sophisticated gut-brain-taste axis that integrates peripheral gustatory signals with central homeostatic and hedonic mechanisms. Hormones such as glucagon-like peptide-1, leptin, ghrelin, and CCK not only regulate appetite and energy balance but also directly influence taste receptor expression and function in the tongue and gastrointestinal tract. Concurrently, neuromodulators like dopamine, serotonin, and norepinephrine fine-tune taste sensitivity at both peripheral (taste buds) and central (reward circuitry) levels, linking chemosensation to motivational states. These interactions are further complicated by metabolic conditions such as obesity and diabetes, where hormonal resistance (e.g., leptin, insulin) and neurotransmitter dysregulation contribute to altered taste preferences and compulsive eating behaviors.

26 February 2026 in Life
Verified
Journal Article
Open access
PDF file
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
OGOscar Josué Gómez-Romero
Oscar Josué Gómez-Romero
EEEtual Espinosa-Cárdenas
Etual Espinosa-Cárdenas
Claudia Ramirez-RenteriaClaudia Ramirez-Renteria
Claudia Ramirez-Renteria
Jose Luis Eduardo Doval CaballeroJose Luis Eduardo Doval Caballero
Jose Luis Eduardo Doval Caballero
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
Insulin therapy remains essential for the management of diabetes mellitus; however, conventional subcutaneous injection continues to impose significant physical, psychological, and behavioral barriers that negatively affect treatment adherence and metabolic outcomes. Injection-related pain, fear of needles, local tissue complications, and psychological insulin resistance contribute to delayed insulin initiation, inadequate dose titration, and suboptimal glycemic control worldwide. In response, alternative insulin delivery routes (including oral, pulmonary, nasal, and transdermal strategies) have been explored to reduce invasiveness and improve patient experience. Among these, transdermal insulin delivery has emerged as a particularly promising approach due to its potential to bypass gastrointestinal degradation, provide controlled absorption, and enhance patient acceptance. Recent advances in microneedle-based systems and needle-free jet injectors have enabled effective transdermal insulin administration by overcoming the skin barrier while minimizing pain and discomfort. This narrative review synthesizes current evidence on insulin delivery technologies with a specific focus on transdermal and needle-free systems. We discuss the biological and physicochemical challenges of insulin transport, the mechanisms underlying emerging delivery platforms, and clinical evidence regarding metabolic efficacy, glycemic variability, and patient-reported outcomes. The integration of these technologies with continuous glucose monitoring is also explored. Finally, we address translational challenges and future perspectives, highlighting the role of needle-free insulin delivery as a patient-centered strategy to improve adherence and metabolic control in diabetes care.

16 July 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
Jose Luis Eduardo Doval CaballeroJose Luis Eduardo Doval Caballero
Jose Luis Eduardo Doval Caballero
DUDaniel Uribe-Cortés
Daniel Uribe-Cortés
GEGenesis Dinora Eugenio-Ponce
Genesis Dinora Eugenio-Ponce
MSMariela Ibarra Salce
Mariela Ibarra Salce
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
Background/Objectives: Type 2 diabetes is increasingly recognized as a systemic disorder driven not only by chronic hyperglycemia and insulin resistance, but also by dysregulated interorgan communication. Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as biologically active carriers of proteins, lipids, and microRNAs capable of modulating gene expression in recipient cells. This narrative review integrates clinical, experimental, and translational evidence on EV-associated microRNAs as candidate biomarkers and potential mediators of diabetic complications, with emphasis on diabetic neuropathy, diabetic kidney disease, diabetic retinopathy, and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This review was aligned with the SANRA framework and focused on biological plausibility, evidence from tissue and biofluids, biomarker potential, therapeutic implications, and barriers to clinical translation. Studies were additionally interpreted according to biological matrix, EV-carrier specificity, analytical platform, study design, and level of functional validation. Results: Across complications, EV-associated microRNAs appear to participate in shared pathogenic processes, including oxidative stress, inflammation, endothelial dysfunction, fibrosis, angiogenesis, neurodegeneration, and metabolic memory. In diabetic neuropathy, microRNAs such as miR-146a, miR-155, miR-21-5p, and miR-148a-3p have been linked to neuroinflammation, Schwann-cell dysfunction, axonal injury, and neuropathic pain. In diabetic kidney disease, miR-21, miR-29, miR-30, and miR-126 are implicated in podocyte injury, tubulointerstitial fibrosis, albuminuria, and microvascular dysfunction. In diabetic retinopathy, microRNAs including miR-146a, miR-155, miR-21, miR-126, and miR-200b contribute to neurovascular injury, inflammation, barrier disruption, and angiogenesis. In MASLD associated with diabetes, hepatocyte-derived EVs carrying microRNAs such as miR-1 and miR-126a-3p may link hepatic lipotoxicity to endothelial inflammatory and β-cell dysfunction. Conclusions: Although EV-associated microRNAs offer promising opportunities for biomarker discovery, risk stratification, and targeted therapies, clinical translation remains limited by heterogeneity in EV isolation, microRNA quantification, biological matrices, and outcome definitions. Distinguishing EV-associated miRNAs from total circulating extracellular miRNAs remains essential for biological interpretation. Standardized, longitudinal, and externally validated studies are required before these signals can be implemented as actionable tools in precision diabetes care.